Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Mantle-Cell 20Lymphoma, Follicular 13Waldenstrom Macroglobulinemia 12Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma 11Lymphoma, B-Cell 10Leukemia 9Recurrence 8Multiple Myeloma 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphoid 4Leukemia, B-Cell 4Hodgkin Disease 4Bronchiolitis Obliterans Syndrome 4Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Neoplasms 2Lung Neoplasms 2Leukemia, Prolymphocytic 2Leukemia, Myeloid, Acute 2Graft vs Host Disease 2Chromosome 17 deletion 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1

Interventions

Irinotecan 3pembrolizumab 2trimebutine 3-thiocarbamoylbenzenesulfonate 1pralsetinib 1napabucasin 1ibrutinib 1alectinib 1Leucovorin 1KRN-330 1Fluorouracil 1Cyclophosphamide 1Bevacizumab 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Colonic Diseases × ibrutinib × Clear all
NCT03332498 2022-06-03

Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
40 enrolled 12 charts
Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡